This article by Camila Ferezin was originally published on The Green Fund, and appears here with permission.
As medicinal cannabis products become more accessible in Australia, it becomes increasingly important to know how patients can access some themselves.
The Therapeutic Goods Administration (TGA) announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine), allowing select medicinal cannabis products to be available over the counter.
The decision will allow TGA approved low-dose CBD containing products, up to a maximum of 150 mg/day, for use in adults, to be supplied over-the-counter by a pharmacist, without a prescription.